tirzepatide eyes May Lower Risk of Diabetic Retinopathy | Professor Erwin Loh posted on the topic Warning that Ozempic and Mounjaro

Phase 2 clinical trials have demonstrated exceptional efficacy for weight reduction, with up to 24.2% weight loss at 48 weeks with the highest doseresults that exceed those typically observed with existing GLP-1 receptor agonists

Innovation race:Both companies are investing billions in research and development to outpace each other

Lilly Zepbound / Mounjaro (tirzepatide) ~21% mean weight loss at ~72 weeks (top dose) Clear superiority vs Wegovy Growing long-term durability data Takeaway: Zepbound remains the benchmark every obesity drug must beat or meaningfully out-differentiate

3rd-party lab tested with COAs

Discreet, Portable Sharps Disposal Safe Medical Waste Management On-the-Go

The focus remains on documenting how GLP-1 programs are defined, compared, and positioned as a distinct care model, using structural explanations rather than outcomes or treatment guidance.